Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 Combined With Immune Therapies in Advanced or Metastatic Malignancies
Incyte Corporation
Incyte Corporation
Incyte Corporation
PharmaMar
Azienda USL Reggio Emilia - IRCCS
Alliance for Clinical Trials in Oncology
Symphogen A/S
Massachusetts General Hospital
Quadriga Biosciences, Inc.
Xencor, Inc.
Incyte Corporation
Stony Brook University
AbbVie
AbbVie
Incyte Corporation
Incyte Corporation
Abramson Cancer Center at Penn Medicine
Swiss Cancer Institute
Stanford University
INSYS Therapeutics Inc
University of Chicago
M.D. Anderson Cancer Center
National Institutes of Health Clinical Center (CC)
National Cancer Institute (NCI)